Top Magn Reson Imaging 13 : — J Clin Invest 91 : — J Clin Endocrinol Metab 82 : — Results of a randomized controlled clinical trial. Marcus R , Wang O , Sattershite J , Mitlak B The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
J Bone Miner Res 18 : 18 — Osteoporos Int — Eli Lilly Product monograph: Forteo. Toronto, Ontario, Canada : Eli Lilly. J Cell Biol 83 : 93 — An evaluation of the evidence to date.
Can Med Assoc J : — National Institute for Clinical Excellence, Final Appraisal The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women.
Toxicol Pathol 30 : — Tashjian AH , Chabner BA Commentary on clinical safety of recombinant human parathyroid hormone 1—34 in the treatment of osteoporosis in men and postmenopausal women. Am J Clin Nutr 71 : — Osteoporos Int 7 : — Arch Intern Med : — Mosekilde L , Danielsen CC , Gasser J The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents estrogen and calcitonin , human parathyroid hormone 1—38 , and combination therapy, assessed in aged ovariectomized rats.
J Bone Miner Res 4 : — J Bone Miner Res 10 : — Bone 16 : — Osteoporos Int 1 : — J Bone Miner Res 19 : — J Bone Miner Res 13 : — Lindsay R.
J Bone Miner Res 15 : — Oglesby AK , Minshall ME , Shen W , Xie S , Silverman SL The impact of incident vertebral and non-vertebral fragility fractures on Health-Related Quality of Life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women. J Rheumatol 30 : — Oxford University Press is a department of the University of Oxford.
It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.
Sign In or Create an Account. Sign In. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents I.
Biological Activity of PTH. Antiresorptive Therapy. Anabolic Therapy. PTH in Clinical Practice. Hodsman , Anthony B. Oxford Academic. Douglas C. David W. Larry Dian. David A. Steven T.
David L. Michael R. Paul D. Wojciech P. Eric Orwoll , Eric Orwoll. Chui Kin Yuen. Cite Cite Anthony B. Select Format Select format. Permissions Icon Permissions. TABLE 1. A One or more randomized controlled trial s with adequate power, or metaanalysis a B Randomized controlled trial s not meeting all criteria for grade A a C Nonrandomized trial s or cohort studies, plus consensus D Any lower level of evidence supported by consensus including expert opinion. Open in new tab. Open in new tab Download slide.
TABLE 2. Controlled trials of PTH therapy. Design a. Age yr. Total enrolled no. Duration months. Primary outcome. Vertebral fractures. BMD T-score. TABLE 3. Teriparatide Neer et al. Alendronate Black et al.
Risedronate Harris et al. Risedronate Reginster et al. Google Scholar Crossref. Search ADS. Google Scholar PubMed. Receptors for the carboxyl-terminal region of PTH 1—84 are highly expressed in osteocytic cells.
Carboxyl-terminal parathyroid hormone peptide 53—84 elevates alkaline phosphatase and osteocalcin mRNA levels in SaOS-2 cells. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Effect of alendronate on risk fracture in women with low bone density but without vertebral fractures. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.
Meta-analysis of therapies for postmenopausal osteoporosis. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
Two year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Risedronate reduces the risk of clinical vertebral fractures in just 6 months. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodelling in patients with osteoporosis. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Reduction of vertebral fracture risk in post menopausal women with osteoporosis treated with raloxifene.
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study.
Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications.
Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older.
The effect of low-dose estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. Effect of four monthly oral vitamin D3 cholecalciferol supplementation on fractures and mortality in men and women living in the community: a randomised double-blind controlled trial. Alendronate increases the degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women.
A theoretical analysis of the contributions of remodelling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Treatment of osteoporosis with parathyroid peptide hPTH and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone.
Histomorphometric evidence for increased bone turnover and cortical thickness without increased cortical porosity after 2 years of cyclical hPTH 1—34 therapy in women with severe osteoporosis.
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for novo bone formation on quiescent cancellous surfaces. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans. Recombinant human parathyroid hormone 1—34 [teriparatide] improves both cortical and cancellous bone structure.
Treatment with human parathyroid hormone 1—34 for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys Macaca fascicularis. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone 1—34 ] with alendronate in postmenopausal women with osteoporosis.
Effect of parathyroid hormone 1—34 on fractures and bone mineral density in postmenopausal women with osteoporosis. The effect of teriparatide [human parathyroid hormone 1—34 ] therapy on bone density in men with osteoporosis.
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. Safety and efficacy of human parathyroid hormone 1—84 in increasing bone mineral density in postmenopausal osteoporosis.
Effects of human parathyroid hormone 1—34 LY, on bone mass, remodelling, and mechanical properties of cortical bone during the first remodelling cycle in rabbits. Intermittently administered human parathyroid hormone 1—34 treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys.
Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY Anabolic effects of human biosynthetic parathyroid hormone fragment 1—34 , LY, on remodelling and mechanical properties of cortical bone in rabbits. Effects of teriparatide [recombinant human parathyroid hormone 1—34 ] on cortical bone in postmenopausal women with osteoporosis. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Teriparatide [rhPTH 1—34 ] treatment improves the structure of the proximal femur in women with osteoporosis. Assessment of effects of LY [recombinant human parathyroid hormone 1—34 ] on cortical bone using digital x-ray radiogrammetry. Sexual dimorphism in vertebral fragility is more the result of gender differences in age-related bone gain than bone loss. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment.
Effects of current and discontinued estrogen replacement therapy on hip structural geometry: the study of osteoporotic fractures. Radius bone strength in bending, compression and falling and its correlation with clinical densitometry at multiple sites.
Estimation of distal radius failure load with micro-finite element analysis models based on three-dimensional peripheral quantitative computed tomography images. High-resolution MRI and micro-FE for the evaluation of changes in bone mechanical properties during longitudinal clinical trials: application to calcaneal bone in postmenopausal women after one year of idoxifene treatment.
Quantitative magnetic resonance imaging in the calcaneus and femur of women with varying degrees of osteopenia and vertebral deformity status. Role of magnetic resonance for assessing structure and function of trabecular bone. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Prevention of estrogen deficiency-related bone loss with human parathyroid hormone 1—34 : a randomized controlled trial. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis.
The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. Effect of an intermittent weekly dose of human parathyroid hormone 1—34 on osteoporosis: a randomized double-masked prospective study using three dose levels.
Regulation of secretion of parathormone and secretory protein I from separate intracellular pools by calcium dibutyryl, cyclic AMP and 1 -isoproteronol. Teriparatide reduces the incidence of new or worsening back pain in women with osteoporosis. Do bisphosphonates reduce the risk of osteoporotic fractures? The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women.
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone 1—34 for two years and relevance to human safety. Commentary on clinical safety of recombinant human parathyroid hormone 1—34 in the treatment of osteoporosis in men and postmenopausal women. Osteosarcoma of bone in a patient with primary hyperparathyroidism: a case report.
Vitamin D status: effects on parathyroid hormone and 1,dihydroxyvitamin D in postmenopausal women. The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents estrogen and calcitonin , human parathyroid hormone 1—38 , and combination therapy, assessed in aged ovariectomized rats. Resorption is not essential for the stimulation of bone growth by hPTH 1—34 in rats in vivo. Cyclical treatment of osteopenic ovariectomized adult rats with PTH 1—34 and pamidronate.
The anabolic effect of human PTH 1—34 on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate—is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodelling system? Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
The post-PTH experience in men with idiopathic osteoporosis: bisphosphonates versus non-pharmacologic therapy. Differential effects of teriparatide after treatment with ralozifene or alendronate. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. Daily versus cyclic PTH combined with alendronate versus alendronate alone for treatment of osteoporosis.
Incident vertebral fractures during an month observation period following discontinuation of LY [recombinant human parathyroid hormone 1—34 , rhPTH 1—34 ] use in postmenopausal women with osteoporosis. PTH-induced increases in bone density are preserved with estrogen: results from a follow-up year in postmenopausal osteoporosis.
Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
The impact of incident vertebral and non-vertebral fragility fractures on Health-Related Quality of Life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women. Issue Section:. Download all slides. View Metrics. Email alerts Article activity alert.
Advance article alerts. New issue alert. Receive exclusive offers and updates from Oxford Academic. More on this topic Bisphosphonates: Mechanisms of Action.
Meta-Analyses of Therapies for Postmenopausal Osteoporosis. Related articles in Web of Science Google Scholar. Related articles in PubMed Simple parameters of synthetic MRI for assessment of bone density in patients with spinal degenerative disease. Neoadjuvant teriparatide therapy targeting the osteoporotic spine: influence of administration period from the perspective of bone histomorphometry. Hospital Frailty Risk Score predicts adverse events in older patients with hip fractures after surgery: Analysis of a nationwide inpatient database in Japan.
Recovery of gait and function during the first six months after tibial shaft fractures. Citing articles via Web of Science Post-translational modifications: The signals at the intersection of exercise, glucose uptake and insulin sensitivity.
A modern approach to dyslipidemia. One or more randomized controlled trial s with adequate power, or metaanalysis a. Randomized controlled trial s not meeting all criteria for grade A a.
Lindsay, Neer, It is not known whether teriparatide is excreted in human milk, affects human milk production, or has effects on the breastfed infant.
Pediatric patients are at higher baseline risk of osteosarcoma because of open epiphyses. Avoid use due to increased baseline risk of osteosarcoma.
Click to see Full User Manual that accompanies the delivery device. The information contained in this section of forteo. Please confirm below. The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. We encourage you to read the privacy policy of every website you visit.
Younger bone age is characterized by newly formed bone matrix with lower, more heterogeneous bone mineral content. Data are from the AVA Study, a phase 4 randomized, active-comparator-controlled, bone biopsy study. At baseline and prior to the single 3-month biopsy, patients were labeled with demeclocycline and then tetracycline respectively in a day schedule. Longitudinal changes were assessed in the cancellous, endocortical, intracortical and periosteal envelopes using a standard panel of histomorphometric indices.
Data are from the SHOTZ study, a phase 4 randomized, active-comparator-controlled, bone biopsy study. Prior to biopsy, patients were labeled with tetracycline in a day schedule.
Longitudinal changes were assessed in the cancellous, endocortical, intracortical, and periosteal envelopes using a standard panel of histomorphometric indices. These biopsies are from a year-old postmenopausal woman with osteoporosis with a baseline T-score of Mean age: Median duration of exposure to therapy: 19 months maximum 24 months.
Forteo [prescribing information]. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. Cellular and molecular mechanisms of bone remodeling. Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility.
N Engl J Med. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. Ritchie RO.
How does human bone resist fracture? Ann N Y Acad Sci. Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them.
However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. In case of overdose, call the poison control helpline at If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your body's response to teriparatide injection.
Do not let anyone else use your medication. Never share a teriparatide injection pen. Ask your pharmacist any questions you have about refilling your prescription. It is important for you to keep a written list of all of the prescription and nonprescription over-the-counter medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital.
It is also important information to carry with you in case of emergencies. Generic alternatives may be available. Teriparatide Injection pronounced as terr ih par' a tyd. Why is this medication prescribed? How should this medicine be used? Other uses for this medicine What special precautions should I follow? What special dietary instructions should I follow? What should I do if I forget a dose? What side effects can this medication cause?
What should I know about storage and disposal of this medication? Brand names. Other uses for this medicine. What special precautions should I follow? Before using teriparatide injection, tell your doctor and pharmacist if you are allergic to teriparatide, mannitol, any other medications, or any of the ingredients in teriparatide injection. Ask your pharmacist for a list of the ingredients.
0コメント